

DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS

6 MAY 2016

MEMORANDUM FOR ST

ATTN: KEVIN WU

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- 1. Your paper, entitled Ex-Vivo Graft Preservation with Hydrogen Sulfide and Hydrogen Iodide for Suspended Animation of Non-Human Primate (Macaca Mulatta) Upper Extremity Vascularized Composite Allotransplants presented at/published to Association of Surgeons Great Britain and Ireland 11-13 May 2016 with MDWI 41-108, and has been assigned local file #16192.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
- Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

Lineta Steel-Goodwin


PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- 3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- 5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- 9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement: "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans: "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN
 - "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFE	SSIONAL MEDICA	L RESEARCH/TECHNICAL	DUBLICAT	IONIO/DD	FORMER
1. TO: CLINICAL RESEARCH 2. FROM:	(Author's Name, Rank, G	rade, Office Symboli	CMEGUICE	IONS/PR	ESENTATIONS
Kevin Wu	, CTR		X YES	NO	4. PROTOCOL NUMBER: NAVY15-05
5. PROTOCOL TITLE: (NOTE: For each n must be submitted	ew release of medical res for review and approval.)	earch or technical information as a p	oublication/pres	sentation, a	new 59 MDW Form 3039
Ex-vivo Graft Preservation with Hydro	gen Sulfide and Hydro	ogen Selenide for Suspended An	imation of N	on-Human	Primate (Macaca mulatta
TITLE OF MATERIAL TO BE PUBLISHE	D OR PRESENTED:				
Ex-vivo Graft Preservation with Hydro	gen Sulfide and Hydro	gen Iodide for Suspended Anim	ation of Non	-Human P	rimate (Macaca mulatta)
7. FUNDING RECEIVED FOR THIS STUDY	Y? X YES NO F	UNDING SOURCE: JPC8			
8. DO YOU NEED FUNDING SUPPORT FO		OSES: YES NO			
9. IS THIS MATERIAL CLASSIFIED?	YES NO				
10. IS THIS MATERIAL SUBJECT TO ANY AND DEVELOPMENT AGREEMENT (CRAD YES NO NOTE: If the answer is Y	ES then attach a copy of	the Agreement to the Publications/P	ATION THROU TUAL PROPE resentations R	JGH A COL RTY RIGH equest Form	LABORATIVE RESEARCH IS AGREEMENT ETC.?
11. MATERIAL IS FOR: DOMESTIC RECHECK APPROPRIATE BOX OR BOXE	ELEASE FOREIGN F	RELEASE			
CHECK APPROPRIATE BOX OR BOXE 11a. PUBLICATION/JOURNAL (List in	ntended publication/journa	al.)	OF MATERIA	L TO BE P	JBLISHED/PRESENTED.
11b. PUBLISHED ABSTRACT (List in	tended journal.)				
11c. POSTER (To be demonstrated al	meeting: name of meeting	ig, city, state, and date of meeting.)			-
11d. PLATFORM PRESENTATION (A Association of Surgeons of Great E	t civilian institutions: name	e of meeting, state, and date of metir	ng.)		
11e. OTHER (Describe: name of meet					
12. EXPECTED DATE WHEN YOU WILL NE NOTE: All publications/presentations are	EED THE CRD TO SUBM	IT YOUR CLEARED PRESENTATIO	ON/PUBLICAT	ION TO DTI	С
DATE		the belefise recinical information (center (DTIC).		
May 10, 2016			*		
3. 59 MDW PRIMARY POINT OF CONTAC	T (Last Name, First Name	e, M.I., email)		14 DUTY	PHONE/PAGER NUMBER
Corpus Raul S, raul.s.corpus.ctr@mail.m	il.mil			2105394404	
5. AUTHORSHIP AND CO-AUTHOR(S) Lis	t in the order they will app	pear in the manuscript.		21033744	
LAST NAME, FIRST NAME AND M.I. Primary/Corresponding Author	GRADE/RANK	SQUADRON/GROUP/OFFIC	E SYMBOL	INSTI	TUTION (If not 59 MDW)
Kevin Wu	CTR	59MDW ST RESTOR			
Renford Cindass	O-3	59MDW ST RESTOR			
JR Spencer	GS13	59MDW ST RESTOR			
Mark Roth				FHCRC	
Vijay Gorantla				UPitt	
Michael R Davis	O-5	59MDW ST RESTOR			
CERTIFY ANY HUMAN OR ANIMAL RESEA 19, AFMAN 40-401_IP, AND 59 MDWI 41-10 CCURATE MANUSCRIPT FOR PUBLICATION	ON AND/OR PRESENTA		RMED IN STRI MATERIAL A	ICT ACCOR	DANCE WITH 32 CFR Y THAT IT IS AN
S. AUTHOR'S PRINTED NAME, RANK, GRA	102	17. AUTHOR'S SIGNATUR	RE		18. DATE .
evin Wu, CTR	fn	1	1		April 26, 2016
APPROVING AUTHORITY'S PRINTED NA		20. APPROVING AUTHOR	RITY'S SIGNAT	TURE	21, DATE
fichael R Davis, Lt Col, Director-RESTOR, Deputy Commander					April 26, 2016
9 MDW FORM 3039, 20160218 escribed by 59 MDWI 41-108	PREVIOUS EDITIONS ALL OT	CURRENTLY NUSE ON BLUSE HERS ARE OBSOLETE	B 4	-	Page 2 of 3 Pages


PROCESSING OF PROFESSIONAL MEDICAL RES	SEARCH/TECHNICAL PUBLICATIONS/PRE	SENTATIONS			
TO: Other and D					
59 MDW/CRD Contact 292-7141 for email instructions.	23. ASSIGNED PROCESSING REQUEST FILE NUMBER 16192				
24. DATE REVIEWED					
29 Apr 2016					
26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHA	NGES: NO YES If yes, give date.	□ N/A			
27. COMMENTS X APPROVED DISAPPROVED					
The presentation is approved.					
28. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	20 PENERATE OCCUPATION				
Rocky Calcote, PhD, Clinical Res. Administrator	29. REVIEWER SIGNATURE CALCOTE.ROCKY.D.117824 Option upwal by CALCOTE.ROCKY.D.178244444 Option upwal by CALCOTE.ROCKY.D.178244444	30. DATE			
2nd ENDORSEMENT (502 ISG/JAC Use Only)	5844 Detr. 2016.04.29 0e.3727-0509				
31. DATE RECEIVED	100 0177 707				
	32. DATE FORWARDED TO 59 MDW/PA				
33. COMMENTS APPROVED (In compliance with security and policy	review directives.) DISAPPROVED				
34. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	35. REVIEWER SIGNATURE	36. DATE			
Brd ENDORSEMENT (59 MDW/PA Use Only)	The same state of the same sta				
37. DATE RECEIVED	38. DATE FORWARDED TO 59 MDW/SGVU				
6 May 2016	UVO 92000000000000000000000000000000000000				
39. COMMENTS APPROVED (In compliance with security and policy review directives.) DISAPPROVED					
	20				
0. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	41. REVIEWER SIGNATURE	42. DATE			
Christopher Carwile, TSgt/E-6, NCOIC, PA	CARWILE.CHRISTOPHER. STEWART.1280477229 CAMBILCE/BISTOPERSTWART.1280477239 DN certs, celds. Government, our DOO, quarter No. our CAMBILCE/BISTOPERSTWART.1280477239 CAMBILCE/BISTOPERSTWART.1280477239	AND WATER TO SERVICE T			
th ENDORSEMENT (59 MDW/SGVU Use Only)	DIEWARI12804//229 CP-CAMMILECHRSTOPHERSTEWARI.12804/7729 Date: 2016/05/06/1039932 4500	6 May 2016			
3. DATE RECEIVED 44. SEN	IOR AUTHOR NOTIFIED BY PHONE OF APPROVAL C	DR DISAPPROVAL T MESSAGE			
5. COMMENTS APPROVED DISAPPROVED					
6. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	47. REVIEWER SIGNATURE	48. DATE			





Disclaimer

reflext the official view or policy of the Department of Defense, Department of the Army, Department of the Air Force or its The views expressed are those of the authors and do not Components. The experiments reported herein were conducted according to Publication 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended the principles set forth in the National Institute of Health



Surviving soldiers from battelfield injuries are presenting with more complex wound patterns in the extremities and face.



Vascularized composite allotransplantation (VCA)

VASCULARIZED COMPOSITE ALLOGRAFT

FREE TISSUE TRANSFER

LOCAL TISSUE TRANSFER


TISSUE EXPANSION

SKIN GRAFTS

DELAYED PRIMARY CLOSURE


SECONDARY INTENTION

PRIMARY INTENTION





Challenges in vascularized composite allotransplantation (VCA)



- Requires systemic immunosuppression
- Skin is a primary target for rejection
- Limited donor pool
- Few indications
- Shorter period for ischemia time
- Ischemic reperfusion injury



Current Standard of Care for Organ Transplants














Hydrogen Sulfide (H₂S)



H₂S Induces a Suspended Animation-Like State in Mice


Eric Black Stone, Mike Morrison, Mark B. Roth

Science 22 Apr 2005:

Vol. 308, Issue 5721, pp. 518

DOI: 10.1126/science.1108581

- Reversibly reduce the metabolic rate of mice exposed to 80 ppm of hydrogen sulfide
- Core temperature reduced as much as 11°
- Animals in this state for 6 hours and they recover completely





Conclusions

- H₂S may play a role in mitigating onset of acute rejection in porcine VCA model in the absence of immunosuppression
- Potential use for graft preservation strategies in a clinical setting that may require prolonged ischemic periods



Thank You